Real-world clinical evidence on rivaroxaban, dabigatran, and apixaban compared with -vitamin K antagonists in patients with non-valvular atrial fibrillation: a systematic literature review

Expert Rev Pharmacoecon Outcomes Res. 2019 Jun;19(3):243-244. doi: 10.1080/14737167.2019.1592834. Epub 2019 Mar 18.

Authors

Steve Deitelzweig^{1

2}, Gregory Y H Lip^{3

4}

Affiliations

¹ a Department of Hospital Medicine , Ochsner Clinic Foundation , New Orleans , LA , USA.
² b School of Medicine, Ochsner Clinical School , The University of Queensland , New Orleans , LA , USA.
³ c Liverpool Centre for Cardiovascular Science , University of Liverpool and Liverpool Heart & Chest Hospital , Liverpool , UK.
⁴ d Aalborg Thrombosis Research Unit, Department of Clinical Medicine , Aalborg University , Aalborg , Denmark.

PMID: 30870051
DOI: 10.1080/14737167.2019.1592834

No abstract available

Keywords: Anticoagulation; direct oral anticoagulants; non-valvular atrial fibrillation; real-world evidence; stroke prevention.

Publication types

Letter
Comment

MeSH terms

Atrial Fibrillation*
Dabigatran
Humans
Pyrazoles
Pyridones
Rivaroxaban*
Vitamin K / antagonists & inhibitors

Substances

Pyrazoles
Pyridones
Vitamin K
apixaban
Rivaroxaban
Dabigatran